<DOC>
	<DOCNO>NCT01068132</DOCNO>
	<brief_summary>Italian , multicentre , non comparative trial patient advance Colorectal Cancer ( CRC ) KRAS wild-type , define molecular evaluation . Patients receive Cetuximab + FOLFIRI disease progression , unacceptable toxicity develop patient refusal . The aim study assess prognostic role PTEN term Progression free survival . Although role Cetuximab first line treatment metastatic CRC soon establish , still unclear best schedule Cetuximab role biological factor order select appropriate subset pt recommend Cetuximab . The data support benefit Cetuximab KRAS wild-type pt open perspective study role molecular marker subset pt . On basis consideration study aim test different schedule Cetuximab good characterize prognosis pt Cetuximab appropriate .</brief_summary>
	<brief_title>Prognostic Factors Patients With Advanced Colorectal Cancer Treated With Cetuximab .</brief_title>
	<detailed_description>Pts meeting eligibility criterion register , provide availability material molecular analysis . Tumour specimen blood sample collect perform genomic , ICH proteomic analysis order identify molecular characteristic tumour . After availability KRAS evaluation , data KRAS wild-type pt collect . Access registration system allow via web . Patients , KRAS wild-type receive : - Cetuximab+FOLFIRI : cetuximab 500 mg/ m² start dose , follow everytwo- week dose 500 mg/ m² , give d1 , follow 1 hour FOLFIRI : irinotecan 180 mg/m2 day 1 LV 100 mg/m2 administer 2-hour infusion FU 400 mg/m2 administer intravenous bolus injection , FU 600 mg/m2 22-hour infusion immediately FU bolus injection day 1 2</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion criterion Signed write informed consent biological analysis ( pt ) Signed write informed consent enrolment ( pts KRAS wild type ) Male female age &gt; = 18 year Diagnosis histologically confirm adenocarcinoma colon rectum KRAS evaluation availability wildtype result Metastatic CRC suitable curativeintent resection Availability tumour sample ( able willing provide tumour sample ) blood biological analysis Presence least one lesion measurable unidimensionally compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) . ( index lesion ( ) must lie within irradiated area ) Eastern cooperative oncology groupperformance status ( ECOGPS ) &lt; 2 Exclusion criterion Brain metastasis ( know suspect ) Previous chemotherapy metastatic CRC ( ) . Adjuvant therapy allow chemotherapy treatment free interval &gt; 6 month Surgery ( exclude diagnostic biopsy ) irradiation within 4 week prior study entry Concurrent chronic systemic immune therapy , chemotherapy , hormone therapy indicate study protocol Any investigational agent ( ) within 4 week prior entry Previous exposure HERaxis pathway target therapy Leucocytes &lt; 3.0 x 109/L neutrophil &lt; 1.5 x 109/L , platelet &lt; 100 x 109/L , hemoglobin &lt; 9 g/dL Bilirubin level either normal &gt; 1.5 x ULN ASAT ALAT &gt; 2.5 x ULN ( &gt; 5 x ULN liver metastasis present ) Serum creatinine &gt; 1.5 x ULN Clinically relevant coronary artery disease history myocardial infarction within last 12 month Acute subacute intestinal occlusion history inflammatory bowel disease Preexisting neuropathy &gt; grade 1 Known grade 3 4 allergic reaction component treatment Any concurrent malignancy nonmelanoma skin cancer , carcinoma situ cervix . ( Pts previous malignancy without evidence disease &gt; equal 5 year allow enter trial ) Pregnancy lactation Inadequate contraception ( male female pt ) childbearing procreational potential Known drug abuse/ alcohol abuse Legal incapacity limit legal capacity Medical psychological condition opinion investigator would permit patient complete study sign meaningful inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>KRAS</keyword>
	<keyword>PTEN</keyword>
</DOC>